Gilead Partners with OncoNano Medicine in $300M Drug Delivery Collaboration for Cancer Therapeutics
核心洞察
Gilead Sciences has entered a research collaboration with OncoNano Medicine (搜索) to evaluate the ON-BOARD encapsulation technology with Gilead's undisclosed drug candidate, potentially worth up to $300 million.
The partnership will assess the stability, selectivity and efficacy of Gilead's drug candidate when encapsulated using OncoNano's pH (搜索)-sensitive polymeric micelle platform designed for tumor-specific drug delivery.
OncoNano's ON-BOARD technology leverages pH (搜索) differences in tumor microenvironments to precisely deliver anti-cancer (搜索) payloads while protecting drugs from systemic breakdown.
Gilead Sciences has announced a research collaboration with clinical-stage biotechnology company OncoNano Medicine (搜索) to evaluate the application of OncoNano's proprietary drug delivery platform to one of Gilead's investigational cancer (搜索) therapeutics. The partnership, announced Tuesday, represents a potential $300 million opportunity for OncoNano through upfront payments, milestones, and expansion possibilities.
ON-BOARD Technology Platform
The collaboration centers on OncoNano's ON-BOARD polymeric micelle platform, which utilizes ultra pH (搜索)-sensitive polymeric micelles to encapsulate drugs and respond to cellular environments characteristic of various cancers. This nanotechnology approach is designed to leverage pH as a universal tumor target, enabling precise delivery of anti-cancer (搜索) payloads to the tumor microenvironment.
The platform protects therapeutic payloads from degradation in the body, preventing systemic exposure while ensuring specific release into tumor microenvironments. OncoNano's technology is designed to improve both pharmacokinetic and pharmacodynamic properties of various payloads, ranging from small molecules to large biologics through encapsulation and localized tumor targeting.
Collaboration Structure and Financial Terms
Under the agreement terms, OncoNano and Gilead will collaborate to evaluate the stability, selectivity and efficacy of Gilead's drug candidate when encapsulated by the ON-BOARD technology. OncoNano will receive an upfront payment and is eligible for additional near-term preclinical milestones.
The biotech is also positioned to receive development, regulatory and commercial milestones, plus royalties on net sales for the encapsulated asset. Gilead retains the option to expand the collaboration by nominating an additional target for the ON-BOARD technology. Should Gilead exercise this expansion option, OncoNano would be eligible to receive up to an aggregate of $300 million, comprising upfront payments and milestone payments, plus royalties.
Strategic Context
"Partnering with Gilead underscores the broad applicability of our ON-BOARD platform," said Kartik Krishnan, MD, PhD, CEO of OncoNano Medicine (搜索). "Our platform is designed to localize drug delivery into tumors with high spatial and temporal specificity. We believe it can complement Gilead's oncology expertise to bring effective treatment options to patients."
The partnership represents Gilead's continued commitment to business development activities, particularly in strengthening its portfolios in liver disease, immunology and cancer (搜索). This collaboration follows Gilead's recent decision to terminate its TIGIT (搜索) therapy domvanalimab program, which it had been developing with Arcus Therapeutics (搜索).
Recent Pipeline Developments
The OncoNano partnership comes after Gilead and Arcus Therapeutics (搜索) decided to discontinue their domvanalimab program following disappointing results. The partners terminated the Phase III STAR-221 trial in first-line advanced gastric and esophageal cancers after an interim analysis found no significant improvements in overall survival compared with Bristol Myers Squibb (搜索)'s Opdivo. The companies also terminated the Phase II EDGE-Gastric trial.
The companies have not disclosed which specific Gilead cancer (搜索) drug candidate will be evaluated using the ON-BOARD platform. OncoNano is utilizing its technology to generate a robust oncology pipeline aimed at addressing high unmet medical needs in cancer treatment.